Belief BioMed

11

2025y04m

China approves its first gene therapy for rare disease hemophilia B

SHANGHAI, April 11 (Xinhua) -- China has approved its first gene therapy for hemophilia B, an inherited bleeding disorder caused by the deficiency of the clotting protein factor IX (FIX).The National Medical Products Administration has officially approved

25

2024y09m

Belief BioMed to Collaborate with AskBio to Explore the Potential of New Gene Therapies

SHANGHAI, Sept. 25, 2024 /PRNewswire/ -- Belief BioMed Inc. (BBM), a biotech company focusing on innovative gene therapies, today announced a new strategic collaboration with Asklepios BioPharmaceutical, Inc. (AskBio)

03

2024y01m

Belief BioMed Successfully Completed Dosing of First Subject in the Registrational Clinical Trial for Hemophilia A

SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- Belief BioMed Group (BBM), an industry-leading biotech company focusing on innovative gene therapies, announced the completion of first subject dosing in its registrational clinical trial (CTR20233400) of BBM-H803

21

2023y07m

Special report 2023: Meet 20 women reshaping biopharma

Drugmakers and industry organizations have launched a wave of diversity, equity and inclusion efforts over the last …

24

2023y04m

Belief BioMed Announces a Key Milestone of Dosing Completion for All Subjects in its Registrational Clinical Trial of BBM-H901

SHANGHAI, April 23, 2023 /PRNewswire/ -- Belief BioMed Group (BBM), an industry-leading biotech company focusing on innovative gene therapies, announced today the completion of patient dosing in its Phase III Registrational Clinical Trial (CTR20212816)